华润双鹤(600062.SH)：盐酸吡格列酮分散片获得药品补充申请批准通知书

Core Viewpoint - China Resources Double Crane Pharmaceutical (600062.SH) announced that its subsidiary, Double Crane Tianan Pharmaceutical (Guizhou) Co., Ltd., received the approval notice for the supplementary application of Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration, indicating that the drug has passed the consistency evaluation for generic drug quality and efficacy [1] Group 1 - The approved drug, Pioglitazone Hydrochloride Dispersible Tablets, is used for the treatment of type 2 diabetes [1] - The successful consistency evaluation is expected to enhance future market sales and competitiveness for the company [1] - This achievement will also provide valuable experience for the company in conducting future evaluations of generic drug consistency [1]